Medpace Holdings, Inc. $MEDP Shares Acquired by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 76.5% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 15,444 shares of the company’s stock after purchasing an additional 6,692 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Medpace were worth $7,941,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Clarkston Capital Partners LLC bought a new stake in shares of Medpace in the 2nd quarter valued at $40,569,000. Brighton Jones LLC grew its stake in shares of Medpace by 160.4% in the 3rd quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock valued at $2,087,000 after buying an additional 2,501 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Medpace by 150.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company’s stock worth $8,080,000 after purchasing an additional 9,117 shares in the last quarter. Baillie Gifford & Co. grew its holdings in shares of Medpace by 12.0% during the third quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock valued at $300,679,000 after buying an additional 62,503 shares during the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp boosted its stake in Medpace by 14.8% during the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 55,861 shares of the company’s stock valued at $28,721,000 after purchasing an additional 7,194 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on MEDP shares. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. BMO Capital Markets started coverage on shares of Medpace in a report on Thursday, November 13th. They set a “market perform” rating and a $600.00 price objective on the stock. TD Cowen restated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Truist Financial set a $555.00 price target on shares of Medpace in a research report on Monday, October 27th. Finally, Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Two research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Medpace presently has a consensus rating of “Reduce” and an average price target of $491.27.

Insider Activity at Medpace

In other news, CEO August J. Troendle sold 59,025 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the sale, the chief executive officer directly owned 774,602 shares in the company, valued at $470,787,603.56. This represents a 7.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Susan E. Burwig sold 20,000 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the sale, the vice president directly owned 27,500 shares of the company’s stock, valued at $16,751,625. This represents a 42.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 320,192 shares of company stock worth $192,909,762 in the last quarter. Company insiders own 20.30% of the company’s stock.

Medpace Stock Down 3.6%

Medpace stock opened at $541.27 on Friday. The company has a market capitalization of $15.25 billion, a P/E ratio of 37.85, a PEG ratio of 1.89 and a beta of 1.42. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $628.92. The stock’s 50 day moving average is $580.60 and its 200 day moving average is $536.29.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.